A5000927214- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Treatment and Pharmacology
- COVID-19 and healthcare impacts
- Lanthanide and Transition Metal Complexes
- Cancer-related cognitive impairment studies
- PARP inhibition in cancer therapy
- Economic and Financial Impacts of Cancer
- Advanced MRI Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- COVID-19 Clinical Research Studies
- Infection Control and Ventilation
- Cardiac Imaging and Diagnostics
- Prostate Cancer Treatment and Research
- Sexual Differentiation and Disorders
- Hormonal and reproductive studies
- Pancreatic and Hepatic Oncology Research
- Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Acute Myocardial Infarction Research
NHS Lothian
2022-2023
Edinburgh Cancer Research
2019-2023
University of Edinburgh
2018-2023
Institute of Genetics and Cancer
2023
Western General Hospital
2020-2022
University of Glasgow
2018
BACKGROUND: Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by elevations in cardiac troponin concentrations. Beta-adrenergic receptor blocker renin-angiotensin system inhibitor therapies have been associated with modest cardioprotective effects unselected patients receiving anthracycline chemotherapy. METHODS: In multicenter, prospective, randomized, open-label, blinded end-point trial, breast cancer non-Hodgkin...
Treatment advances have improved cancer-related outcomes and shifted interest towards minimising long-term iatrogenic complications, particularly chemotherapy-related cardiotoxicity. High-sensitivity cardiac troponin I (hs-cTnI) assays accurately quantify very low concentrations of plasma enable early detection cardiomyocyte injury prior to the development myocardial dysfunction. The profile hs-cTnI in response anthracycline-based treatment has not previously been described.This was a...
Abstract Background Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection limited vaccine efficacy. Long–term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity prevalence (SCCAMP) study characterizes the incidence outcomes of vaccination in patients with solid tumors undergoing ACT. This preliminary analysis includes 766 recruited since May 2020. Methods Patients solid-organ cancers attending secondary care active...
Purpose: To explore the utility of phosphorus magnetic resonance spectroscopy ( 31 P MRS) in identifying anthracycline-induced cardiac toxicity patients with breast cancer. Methods: Twenty newly diagnosed cancer receiving anthracycline-based chemotherapy had assessment left ventricular ejection fraction (LVEF) and MRS to determine myocardial Phosphocreatine/Adenosine Triphosphate Ratio (PCr/ATP) at three time points: pre-, mid-, end-chemotherapy. Plasma high sensitivity troponin-I (cTn-I)...
ABSTRACT Background Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by elevations in cardiac troponin concentrations. Beta-adrenergic receptor blocker renin-angiotensin-system inhibitor therapies have been associated with modest cardioprotective effects unselected patients receiving anthracycline chemotherapy. Methods In multicenter prospective randomized open label blinded endpoint trial, breast cancer...
Abstract BACKGROUND Anthracyclines are widely used in the treatment of breast cancer and well recognised to carry increased risk cardiotoxicity. This can occur as an early, acute manifestation or many years after late onset cardiomyopathy. It is increasingly apparent that there may be a chronic subclinical phase associated with low grade cardiac injury no clinical impact on contractile function heart. period remain latent for patient remaining asymptomatic apparently normal function....
Abstract BACKGROUND Treatment advances have improved cancer-related outcomes and shifted interest towards minimising long-term iatrogenic complications, particularly chemotherapy-related cardiotoxicity. High-sensitivity cardiac troponin I (hs-cTnI) assays accurately quantify very low concentrations of plasma enable early detection cardiomyocyte injury prior to development myocardial dysfunction. The profile hs-cTnI in response anthracycline-based treatment has not previously been described....
Abstract PURPOSETo explore the utility of phosphorus magnetic resonance spectroscopy ( 31 P MRS) in identifying anthracycline-induced cardiac toxicity patients with breast cancer.METHODS20 newly diagnosed cancer receiving anthracycline-based chemotherapy had assessment left ventricular ejection fraction (LVEF) and MRS to determine myocardial Phosphocreatine/Adenosine Triphosphate ratio (PCr/ATP) at three time points: pre, mid end-chemotherapy. Plasma high sensitivity troponin-I (cTn-I) tests...
Abstract Background Cancer and systemic anti-cancer treatment (SACT) have been identified as possible risk factors for infection related severe illness associated with SARS-CoV-2 virus a consequence of immune suppression. The Scottish COVID CAncer iMmunity Prevalence (SCCAMP) study aims to characterise the incidence outcomes SARS-Cov-2 in patients undergoing active during COVID-19 pandemic their antibody response following vaccination. Patients Methods Eligible were those attending secondary...
Background: Cancer and systemic anti-cancer treatment (SACT) have been identified as possible risk factors for infection related severe illness associated with SARS-CoV-2 virus a consequence of immune suppression. The Scottish COVID CAncer iMmunity Prevalence (SCCAMP) study aimed to characterise the incidence outcomes SARS-Cov-2 in patients undergoing active during COVID-19 pandemic their antibody response following vaccination.Patients Methods: Eligible were those attending secondary care...
e18733 Background: Cancer and systemic anti-cancer treatment (SACT) have been identified as possible risk factors for infection related severe illness associated with SARS-CoV-2 virus a consequence of immune suppression. The Scottish COVID CAncer iMmunity Prevalence (SCCAMP) study aimed to characterise the incidence outcomes SARS-Cov-2 in patients undergoing active during COVID-19 pandemic their antibody response following vaccination. Methods: Eligible were those attending secondary care...